🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

445 results for “SK” Clear

  1. GSK influenza virus H5N1 vaccine 1557484A

    United Therapeutics Europe Ltd

    Influenza

    phase 2 mab terminated

    1 trial

  2. GSK1070806

    GlaxoSmithKline

    Dermatitis, Atopic

    phase 2 small molecule terminated

    1 trial

  3. GSK221149A

    GlaxoSmithKline

    Obstetric Labour, Premature

    phase 2 small molecule completed

    1 trial

  4. GSK2330672

    ELITE PHARMACEUTICALS INC /NV/

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  5. GSK233705 12.5mcg

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  6. GSK256066

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  7. GSK3196165 Dose 1

    GlaxoSmithKline

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  8. GSK4418959

    IDEAYA Biosciences

    Neoplasms, Colorectal

    phase 2 small molecule active

    1 trial

  9. GSK4527226

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  10. GSK598809

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule completed

    1 trial

  11. GSK962040 50 mg

    GlaxoSmithKline

    Gastroparesis

    phase 2 small molecule terminated

    2 trials

  12. GTB-3550 TriKE® Phase I

    GT Biopharma

    High-risk Myelodysplastic Syndromes

    phase 2 small molecule terminated

    1 trial

  13. Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, JNJ-42756493, Gemcitabine 2 g Powder for Solution for Infusion, JNJ-42756493, JNJ-42756493, Mitomycin medac 1 mg/ml Pulver zur Herstellung einer Injektions- bzw. Infusionslösung oder einer Lösung zur intravesikalen Anwendung

    Janssen-Cilag International N.V.

    Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions

    phase 2 small molecule active

    1 trial

  14. HT-001, HT-001, The corresponding placebo is formulated using the same excipients as HT-001 and is identical in color and physical appearance., HT-001

    Hoth Therapeutics

    Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors

    phase 2 small molecule active

    1 trial

  15. Humanized IgG1 monoclonal antibody against GD2, Leukine

    Y-Mabs Therapeutics A/S

    Treatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow

    phase 2 small molecule active

    1 trial

  16. Hyaluronidase

    Amphastar France Pharmaceuticals

    Allergic Skin Reaction

    phase 2 small molecule completed

    1 trial

  17. IVERMECTIN

    The George Institute

    Strongyloidiasis is caused by a parasite that is globally distributed in tropical and sub-tropical areas. Most patients with strongyloidiasis are asymptomatic or have mild symptoms with gastrointestinal disturbances, respiratory symptoms, and skin lesions. In situations of low defenses (patients under treatment with corticosteroids, organ transplant recipients or other situations) they can present serious complications with high mortality.

    phase 2 small molecule active

    1 trial

  18. Ilofotase alfa, Ilofotase alfa Placebo Drug Product

    Lacuna Pharma Pty Ltd

    Risk for renal damage following open heart surgery

    phase 2 small molecule active

    1 trial

  19. Interactive injection and sexual risk intervention

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  20. Intravenous esketamine using Dixon's up-and-down sequential method

    The First People's Hospital of Lianyungang

    Hepatic Neoplasm

    phase 2 small molecule active

    1 trial

  21. Ipilimumab, OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab

    The George Institute

    Adjuvant therapy after salvage surgery of high risk recurrent head and neck squamous cell carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  22. Isis 420915/GSK 299872

    IONIS PHARMACEUTICALS INC

    Amyloidosis

    phase 2 small molecule terminated

    1 trial

  23. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Fondazione Telethon ETS

    high-risk soft tissue sarcoma of the extremity (undifferentiated pleomorphic sarcoma or dedifferentiated/pleomorphic liposarcoma, tumor size > 5 cm, grade 2 or 3 out of 3)

    phase 2 small molecule active

    1 trial

  24. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Saline solution NACl 0.9%, mRNA-4157

    Merck Sharp and Dohme

    Intermediate-high -risk RCC, high-risk RCC who have undergone nephrectomy, or M1 NED RCC who have undergone nephrectomy and metastasectomy.

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources